Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 56

1.

Rationale and design of the MASTERPLAN study: Multifactorial approach and superior treatment efficacy in renal patients with the aid of nurse practitioners.

Van Zuilen AD, Wetzels JF, Blankestijn PJ, Bots ML, Van Buren M, Ten Dam MA, Kaasjager KA, Van De Ven PJ, Vleming LJ, Ligtenberg G, Ligtenberg G; MASTERPLAN Study Group.

J Nephrol. 2005 Jan-Feb;18(1):30-4.

PMID:
15772920
2.

MASTERPLAN: study of the role of nurse practitioners in a multifactorial intervention to reduce cardiovascular risk in chronic kidney disease patients.

Van Zuilen AD, Wetzels JF, Bots ML, Van Blankestijn PJ; MASTERPLAN Study Group.

J Nephrol. 2008 May-Jun;21(3):261-7.

PMID:
18587712
3.

Multifactorial approach and superior treatment efficacy in renal patients with the aid of nurse practitioners. Design of The MASTERPLAN Study [ISRCTN73187232].

van Zuilen AD, van der Tweel I, Blankestijn PJ, Bots ML, van Buren M, ten Dam MA, Kaasjager KA, van de Ven PJ, Vervoort G, Vleming LJ, Ligtenberg G, Wetzels JF; MASTERPLAN study group.

Trials. 2006 Mar 30;7:8.

4.

Quality of care in patients with chronic kidney disease is determined by hospital specific factors.

van Zuilen AD, Blankestijn PJ, van Buren M, ten Dam MA, Kaasjager KA, Ligtenberg G, Sijpkens YW, Sluiter HE, van de Ven PJ, Vervoort G, Vleming LJ, Bots ML, Wetzels JF; MASTERPLAN Study Group.

Nephrol Dial Transplant. 2010 Nov;25(11):3647-54. doi: 10.1093/ndt/gfq184. Epub 2010 Apr 9.

PMID:
20382963
5.

Nurse practitioner care improves renal outcome in patients with CKD.

Peeters MJ, van Zuilen AD, van den Brand JA, Bots ML, van Buren M, Ten Dam MA, Kaasjager KA, Ligtenberg G, Sijpkens YW, Sluiter HE, van de Ven PJ, Vervoort G, Vleming LJ, Blankestijn PJ, Wetzels JF.

J Am Soc Nephrol. 2014 Feb;25(2):390-8. doi: 10.1681/ASN.2012121222. Epub 2013 Oct 24.

6.

Multifactorial intervention with nurse practitioners does not change cardiovascular outcomes in patients with chronic kidney disease.

van Zuilen AD, Bots ML, Dulger A, van der Tweel I, van Buren M, Ten Dam MA, Kaasjager KA, Ligtenberg G, Sijpkens YW, Sluiter HE, van de Ven PJ, Vervoort G, Vleming LJ, Blankestijn PJ, Wetzels JF.

Kidney Int. 2012 Sep;82(6):710-7. doi: 10.1038/ki.2012.137. Epub 2012 Jun 27.

7.

Nurse practitioners improve quality of care in chronic kidney disease: two-year results of a randomised study.

van Zuilen AD, Blankestijn PJ, van Buren M, ten Dam MA, Kaasjager KA, Ligtenberg G, Sijpkens YW, Sluiter HE, van de Ven PJ, Vervoort G, Vleming L, Bots ML, Wetzels JF.

Neth J Med. 2011 Nov-Dec;69(11):517-26.

8.
9.

[Drawing up guidelines for the attendance of physical health of patients with severe mental illness].

Saravane D, Feve B, Frances Y, Corruble E, Lancon C, Chanson P, Maison P, Terra JL, Azorin JM; avec le soutien institutionnel du laboratoire Lilly.

Encephale. 2009 Sep;35(4):330-9. doi: 10.1016/j.encep.2008.10.014. Epub 2009 Jul 9. French.

PMID:
19748369
10.

Preventing coronary heart disease and stroke with aggressive statin therapy in older adults using a team management model.

Mason CM.

J Am Acad Nurse Pract. 2009 Jan;21(1):47-53. doi: 10.1111/j.1745-7599.2008.00373.x. Review.

PMID:
19125895
11.

What have we learned from the current trials?

Abbott KC, Bakris GL.

Med Clin North Am. 2004 Jan;88(1):189-207. Review.

PMID:
14871059
12.

The WHO antenatal care randomised controlled trial: rationale and study design.

Villar J, Bakketeig L, Donner A, al-Mazrou Y, Ba'aqeel H, Belizán JM, Carroli G, Farnot U, Lumbiganon P, Piaggio G, Berendes H.

Paediatr Perinat Epidemiol. 1998 Oct;12 Suppl 2:27-58.

PMID:
9805722
13.

Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial: design and methods.

ACCORD Study Group, Buse JB, Bigger JT, Byington RP, Cooper LS, Cushman WC, Friedewald WT, Genuth S, Gerstein HC, Ginsberg HN, Goff DC Jr, Grimm RH Jr, Margolis KL, Probstfield JL, Simons-Morton DG, Sullivan MD.

Am J Cardiol. 2007 Jun 18;99(12A):21i-33i. Epub 2007 Apr 16.

PMID:
17599422
14.

A randomized, controlled trial for risk factor reduction in patients with symptomatic vascular disease: the multidisciplinary Vascular Prevention by Nurses Study (VENUS).

Goessens BM, Visseren FL, Sol BG, de Man-van Ginkel JM, van der Graaf Y; SMART Study Group.

Eur J Cardiovasc Prev Rehabil. 2006 Dec;13(6):996-1003.

PMID:
17143135
16.

[Arterial hypertension and dyslipidemia in patients with chronic kidney disease (CKD). Anti-platelet aggregation. Goal oriented treatment].

Cases Amenós A, Goicoechea Diezhandiño M, de Alvaro Moreno F.

Nefrologia. 2008;28 Suppl 3:39-48. Spanish.

17.

[Controlled randomized clinical trials].

Jaillon P.

Bull Acad Natl Med. 2007 Apr-May;191(4-5):739-56; discussion 756-8. French.

PMID:
18225427
18.

Early and intensive therapy for management of hyperglycemia and cardiovascular risk factors in patients with type 2 diabetes.

Dailey G.

Clin Ther. 2011 Jun;33(6):665-78. doi: 10.1016/j.clinthera.2011.04.025. Review.

PMID:
21704233
19.

Clinical practice guidelines for managing dyslipidemias in kidney transplant patients: a report from the Managing Dyslipidemias in Chronic Kidney Disease Work Group of the National Kidney Foundation Kidney Disease Outcomes Quality Initiative.

Kasiske B, Cosio FG, Beto J, Bolton K, Chavers BM, Grimm R Jr, Levin A, Masri B, Parekh R, Wanner C, Wheeler DC, Wilson PW; National Kidney Foundation.

Am J Transplant. 2004;4 Suppl 7:13-53.

20.

Supplemental Content

Support Center